Physician profile
Mark Anthony Raphael
NPI 1922428382
$20,109.62
in general payments reported to CMS, 2019-2025
28 companies · $15K in 2025
The $15K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $568 · 2021: $952 · 2022: $987 · 2023: $986 · 2024: $589 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $2,596 · Travel and Lodging: $1,866 · Education: $27.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,225.83 |
| Food and Beverage | $2,595.63 |
| Travel and Lodging | $1,865.57 |
| Education | $27.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $14,427.69 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $1,426.06 | 2019-2025 | |
| Gilead Sciences, INC. | $807.10 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $611.05 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $506.25 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $478.62 | 2019-2025 | Stelara, Tremfya |
| Ironwood Pharmaceuticals, INC | $248.19 | 2020-2025 | Linzess |
| Janssen Scientific Affairs, LLC | $237.50 | 2019-2020 | |
| Celgene Corporation | $235.77 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $137.86 | 2022-2025 | Dupixent |
| Olympus America INC. | $128.40 | 2019 | |
| Braintree Laboratories, INC. | $113.71 | 2020-2022 | |
| Pfizer INC. | $112.75 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $88.33 | 2021 | |
| Madrigal Pharmaceuticals | $68.63 | 2025 | Rezdiffra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $66.48 | 2021-2023 | Sucraid |
| Ferring Pharmaceuticals INC. | $63.92 | 2020-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $47.97 | 2020-2024 | |
| Celltrion USA INC. | $44.30 | 2024-2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $44.30 | 2023-2024 | Bylvay, Iqirvo |
| Daiichi Sankyo INC. | $42.34 | 2023 | Injectafer |
| Capsovision, INC. | $36.17 | 2024-2025 | Capsocam Plus |
| Lilly USA, LLC | $35.95 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $29.76 | 2021 | |
| Fresenius Kabi USA, LLC | $19.99 | 2023 | Idacio |
| Ardelyx, INC. | $19.82 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $17.02 | 2024 | |
| Genzyme Corporation | $13.69 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Raphael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.